Telmisartan in hypertension coexisting with diabetes or dyslipidaemia – patients’ selection Review article

Main Article Content

Marek Chmielewski
Marek Kuch
Paweł Piątkiewicz

Abstract

Hypertension frequently coexists with dyslipidaemia or diabetes. The combination of these conditions leads to increased risk of cardiovascular complications. The results of the ONTARGET trial confirm the efficacy of telmisartan in the prevention of cardiovascular disease in people at high risk, including diabetes and nephropathy.

Article Details

How to Cite
Chmielewski , M., Kuch , M., & Piątkiewicz , P. (2017). Telmisartan in hypertension coexisting with diabetes or dyslipidaemia – patients’ selection. Medycyna Faktow (J EBM), 10(1(34), 30-33. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2190
Section
Articles

References

1. Telmisartan [online].
2. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diab. Klin. (Clinical Diabetology) 2016; 5(Supl. A).
3. Yusuf S., Teo K.K., Pogue J. et al.: ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
4. Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1(1): 1-70.
5. Inoue T., Morooka T., Moroe K. et al.: Effect of telmisartan on cholesterol levels in patients with hypertension – Saga Telmisartan Aggressive Research (STAR). Horm. Metab. Res. 2007; 39(5): 372-376.
6. Usui I., Fujisaka S., Yamazaki K. et al.: Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res. Clin. Pract. 2007; 77(2): 210-214.
7. Jayapriya B., Thamilarasi S., Shanthi M. et al.: Effect of telmisartan on blood pressure and lipid profile in hypertensive patients with dyslipidemia. IJPLS 2013; 4(10): 3035-3040.